. However, the impact of STN-DBS on the progression of PD is unknown. Previous preclinical studies have demonstrated that STN-DBS can attenuate the degeneration of a relatively intact nigrostriatal system from dopamine (DA)-depleting neurotoxins. The present study examined whether STN-DBS can provide neuroprotection in the face of prior significant nigral DA neuron loss similar to PD patients at the time of diagnosis. STN-DBS between 2 and 4 weeks after intrastriatal 6-hydroxydopamine (6-OHDA) provided significant sparing of DA neurons in the SN of rats. This effect was not due to inadvertent lesioning of the STN and was dependent upon proper electrode placement. Since STN-DBS appears to have significant neuroprotective properties, initiation of STN-DBS earlier in the course of PD may provide added neuroprotective benefits in addition to its ability to provide symptomatic relief.
Introduction
Deep brain stimulation of the subthalamic nucleus (STN-DBS) is now the most frequently practiced surgical therapy for the treatment of Parkinson's disease (PD). The efficacy of STN-DBS in the relief of the cardinal motor symptoms of PD is well documented with recent reports indicating that symptomatic relief is both long-lasting and comparable to the best medical therapy (Krack et al., 2003; Schupbach et al., 2005; Weaver et al., 2009) . However, the clinical use of this treatment has proceeded without systematic study of the impact of STN-DBS on the progression of the disease itself. Currently, PD patients are not considered candidates for STN-DBS unless symptoms have been present for a minimum of 5 years (Chang and Chou, 2006; Neimat et al., 2006) . The average PD patient has a mean disease duration of 14 years before STN-DBS is performed (Volkmann, 2004) during which time it is likely that the disease has progressed significantly (Goetz et al., 2000) . Therefore, by the time patients initiate DBS therapy they are well into the later stages of PD, which makes it difficult to determine whether STN-DBS can preserve remaining DA neurons. Positive indications of STN-DBS' neuroprotective efficacy in parkinsonian animal models would suggest that expansion of this treatment to PD patients in early and moderate stages of the disease should be seriously considered.
Preclinical studies in both rats and monkeys have demonstrated that STN-DBS can prevent the degeneration of nigral dopamine (DA) neurons from the insult produced by DA-depleting neurotoxins (Harnack et al., 2008; Maesawa et al., 2004; Temel et al., 2006; Wallace et al., 2007) . While these studies are a promising preliminary indication of STN-DBS' neuroprotective potential, the overwhelming majority of nigral DA neurons were present when STN stimulation was initiated either immediately prior to, or soon after toxin administration. While this experimental paradigm provides the best opportunity to observe neuroprotection, it is confounded by the possibility that the reduction in nigral DA neuron degeneration associated with STN-DBS is due to prevention of toxin uptake/metabolism and does not accurately model the DA neuron loss that already exists in PD patients who undergo the procedure.
In the present study, we utilized unbiased stereology and analysis of striatal DA to characterize the time course and magnitude of nigral DA neuron and dopaminergic terminal loss following unilateral intrastriatal 6-OHDA injection to rats. Our goal was to precisely define the rate of progression of the relatively protracted nigrostriatal degeneration induced by intrastriatal 6-OHDA and then utilize these same Neurobiology of Disease 39 (2010) [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] 
